Last reviewed · How we verify

JNJ-90301900 (NBTXR3) — Competitive Intelligence Brief

JNJ-90301900 (NBTXR3) (JNJ-90301900 (NBTXR3)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nanoparticle radiosensitizer. Area: Oncology.

phase 3 Nanoparticle radiosensitizer Hafnium oxide nanoparticles (radiation dose amplification) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

JNJ-90301900 (NBTXR3) (JNJ-90301900 (NBTXR3)) — Johnson & Johnson Enterprise Innovation Inc.. NBTXR3 is a nanoparticle hafnium oxide that concentrates radiation dose within tumor cells, enhancing the cytotoxic effects of radiotherapy.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
JNJ-90301900 (NBTXR3) TARGET JNJ-90301900 (NBTXR3) Johnson & Johnson Enterprise Innovation Inc. phase 3 Nanoparticle radiosensitizer Hafnium oxide nanoparticles (radiation dose amplification)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nanoparticle radiosensitizer class)

  1. Johnson & Johnson Enterprise Innovation Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). JNJ-90301900 (NBTXR3) — Competitive Intelligence Brief. https://druglandscape.com/ci/jnj-90301900-nbtxr3. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: